Previous Close | 11.90 |
Open | 11.90 |
Bid | 10.00 |
Ask | 14.50 |
Strike | 60.00 |
Expire Date | 2024-09-20 |
Day's Range | 11.90 - 11.90 |
Contract Range | N/A |
Volume | |
Open Interest | 5 |
Sanofi CEO Paul Hudson thinks AI offers 'insane' potential for the pharmaceutical industry, which can spend up to $4 billion developing a drug.
In recent trading sessions, France's CAC 40 Index has experienced a modest decline of 0.89%, reflecting broader European market uncertainties and mixed signals regarding future interest rate cuts. Amidst this backdrop, dividend stocks on Euronext Paris continue to attract attention for their potential to offer investors steady income streams in a fluctuating market environment. A key consideration for selecting strong dividend stocks involves not just the yield but also the sustainability...
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.